Skip to main content
BBIO
NASDAQ Life Sciences

BridgeBio's BBP-418 Delivers Strong Phase 3 Results for LGMD2I/R9; NDA Filing Set for H1 2026

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$71.39
Mkt Cap
$13.84B
52W Low
$28.325
52W High
$84.94
52W Position info
152% above low
Off High info
16% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

BBIO has more than doubled off its 52-week low of $28.325.

Summary

BridgeBio Pharma announced highly positive interim analysis results from its Phase 3 FORTIFY clinical trial for BBP-418 in patients with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). The data demonstrated consistent efficacy, including early and sustained improvements in ambulation and reduction in serum creatine kinase, coupled with a favorable safety profile comparable to placebo. This specific positive Phase 3 data for BBP-418 provides concrete details following the company's general statement in its recent 10-K about positive Phase 3 data for pipeline drugs and planned 2026 regulatory submissions. The company now intends to submit a New Drug Application (NDA) to the FDA in the first half of 2026, with a potential U.S. launch anticipated in late 2026 or early 2027. If approved, BBP-418 could be the first therapy for LGMD2I/R9, representing a significant commercial opportunity and a major catalyst for the company's valuation. Investors will now focus on the NDA submission timeline and subsequent FDA review process.

At the time of this announcement, BBIO was trading at $71.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.8B. The 52-week trading range was $28.33 to $84.94. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

BBIO - Latest Insights

BBIO
Oct 29, 2026, 4:52 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $70.69
Real-time Price: $74.36 info
Change: +$3.67 (+5%) info
Market Cap: $14.472B info
BBIO
Oct 29, 2026, 4:03 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $71.44
Real-time Price: $74.36 info
Change: +$2.92 (+4%) info
Market Cap: $14.472B info
BBIO
Oct 29, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $70.67
Real-time Price: $74.36 info
Change: +$3.69 (+5%) info
Market Cap: $14.472B info
BBIO
Oct 13, 2026, 6:01 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $65.75
Real-time Price: $74.36 info
Change: +$8.61 (+13%) info
Market Cap: $14.472B info
BBIO
Oct 11, 2026, 2:30 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $65.35
Real-time Price: $74.36 info
Change: +$9.01 (+14%) info
Market Cap: $14.472B info